Development of Early Diagnosis of Parkinson's Disease Using Premotor Symptoms and Blood Changes as Biomarkers.

Autor: Gusev, E. I., Katunina, E. A., Martinov, M. Yu., Blokhin, V. E., Kalinkin, A. L., Alesenko, A. V., Nodel, M. R., Malykhina, E. A., Titova, N. V., Katunin, D. A., Shupik, M. A., Gutner, U. A., Maloshitskaya, O. A., Sokolov, S. A., Kucheryanu, V. G., Pavlova, E. N., Ugrumov, M. V.
Předmět:
Zdroj: Neuroscience & Behavioral Physiology; Oct2021, Vol. 51 Issue 8, p1050-1058, 9p
Abstrakt: Objectives. To identify changes in the biochemical composition of the plasma in a group of patients at risk of developing Parkinson's disease (PD) at the prodromal stage in comparison with age-matched controls. Materials and methods. Subjects in the risk group were selected on the basis of the having impairments to sleep, olfaction, and peristalsis. The risk group consisted of 12 people and the control group of eight people. Results. The results showed that of seven catecholamines and their metabolites, the only blood change was in the L-dihydroxyphenylalanine (L-DOPA) level, which decreased in the risk group from the level in controls. A decreased L-DOPA concentration is regarded as a marker for selective degeneration of central and peripheral catecholaminergic neurons in PD. In contrast to L-DOPA, the blood concentrations of seven of 12 sphingomyelins increased. Given that changes in sphingomyelin metabolism are linked with apoptosis, autophagy, and synucleinopathies, increases in their concentrations in the risk group are regarded as indicators of systemic degeneration of central and peripheral neurons. Furthermore, the risk group showed a tendency to decreased urate concentrations, which are endogenous neuroprotectors. Conclusions. The results obtained here suggest that changes in blood L-DOPA, sphingomyelin, and urate levels can serve as diagnostic markers for the development of PD at the prodromal stage. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: